Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Предменструальный синдром и возможности фитотерапии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Психосоматические и поведенческие изменения перед менструацией, ощущаемые большинством женщин, могут нарушать повседневную активность, отношения с окружением и качество жизни, превращаясь в заболевание – предменструальный синдром (ПМС). Этиология ПМС остается неясной, четкие, универсальные диагностические критерии отсутствуют, что приводит к недостаточно эффективной диагностике и терапии. Гормональная терапия ПМС является одним из ведущих методов устранения симптомов, возникающих в лютеиновую фазу, но и она имеет ряд ограничений, а иногда вызывает побочные эффекты, которые нивелируют пользу ее применения. Психотропные средства являются препаратами выбора при предменструальном дисфорическом расстройстве, но длительное их применение обычно не рекомендуется из-за возможности привыкания и возникновения побочных реакций. Остается актуальным поиск средств снижения выраженности или устранения симптомов ПМС не только среди лекарственных препаратов, но и среди средств фитотерапии, немедикаментозных методов воздействия.
Ключевые слова: предменструальный синдром, предменструальное дисфорическое расстройство, серотонинергические вещества, фитотерапия.
Ключевые слова: предменструальный синдром, предменструальное дисфорическое расстройство, серотонинергические вещества, фитотерапия.
________________________________________________
Psychosomatic and behavioral changes before menstruation, perceived by the majority of women violate daily activities, relationships with the environment and quality of life, becoming a disease by the name of premenstrual syndrome (PMS). The etiology of PMS remains unclear and concise, universal diagnostic criteria are missing, which leads to the lack of effective diagnosis and therapy. Hormone therapy of the PMS is one of the leading methods to eliminate the symptoms that occur in the luteal phase, but it has some limitations, and sometimes causes side effects that negate the benefits of its application. Psychotropic drugs are the drugs of choice for premenstrual dysphoric disorder, but their long-term use is generally not recommended because of the possibility of addiction and the occurrence of adverse reactions. The research for relevant means of reducing the severity or eliminating the symptoms of PMS, not only among drugs, but also among the means of herbal medicine and non-drug methods of exposure remains important.
Key words: premenstrual syndrome, premenstrual dysphoric disorder, serotonergic agents, herbal medicine.
Полный текст
Список литературы
1. Ледина А.В., Прилепская В.Н., Акимкин В.Г. Предменструальный синдром: распространенность и основные проявления (результаты эпидемиологического исследования). Эпидемиология и вакцинопрофилактика. 2014; 75 (2): 66–71.
2. Yonkers KA, O’Brien S, Eriksson E. Premenstrual syndrome. Lancet 2008; 371 (9619): 1200–10.
3. Gollenberg AL, Hediger ML, Mumford SL et al. Perceived Stress and Severity of Perimenstrual Symptoms: The BioCycle Study. J Womens Health (Larchmt) 2010; 19 (5): 959–67.
4. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
5. Reed SC, Levin FR, Evans SM. Changes in Mood, Cognitive Performance and Appetite in the Late Luteal and Follicular Phases of the Menstrual Cycle in Women With and Without PMDD (Premenstrual Dysphoric Disorder). Horm Behav 2008; 54 (1): 185–93.
6. Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol 2010; 202 (3): 221–31.
7. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harv Rev Psychiatry 2009; 17 (2): 120–37.
8. Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, Sattar K. Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis Study. J Clin Diagn Res 2014; 8 (2): 106–9.
9. Epperson CN, Steiner M, Hartlage SA et al. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. Am J Psychiatry 2012;
169 (5): 465–75.
10. Wichianpitaya J, Taneepanichskul S. A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms. Obstet Gynecol Int 2013; 2013: 487143.
11. Forrester-Knauss C, Stutz EZ, Weiss C, Tschudin S. The interrelation between premenstrual syndrome and major depression: Results from a population-based sample. BMC Public Health 2011; 11: 795.
12. Read JR, Perz J, Ussher JM. Ways of coping with premenstrual change: development and validation of a premenstrual coping measure. BMC Womens Health 2014; 14: 1.
13. Borenstein J, Chiou CF, Dean B et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47: 26–33.
14. Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual Syndrome Prevalence and Fluctuation over Time: Results from a French Population-Based Survey. J Womens Health (Larchmt) 2009; 18 (1): 31–9.
15. Delara M, Borzuei H, Montazeri A. Premenstrual Disorders: Prevalence and Associated Factors in a Sample of Iranian Adolescents. Iran Red Crescent Med J 2013; 15 (8): 695–700.
16. Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006; 27 (4): 201–10.
17. Hartlage SA, Freels A, Gotman N, Yonkers KA. Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69 (3): 300–5.
18. O’Brien PMS, Bäckström T, Brown C et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 2011; 14: 13–21.
19. Payne JL, Palmer JT, Joffe H. A Reproductive Subtype of Depression: Conceptualizing Models and Moving Toward Etiology. Harv Rev Psychiatry 2009; 17 (2): 72–86.
20. Nevatte T, O’Brien PMS, Bäckström T et al. Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16 (4): 279–91.
21. Bäckström T, Haage D, Löfgren M et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011; 191: 46–54.
22. Andréen L, Nyberg S, Turkmen S et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009; 34: 1121–32.
23. Segebladh B, Borgström A, Nyberg S et al. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 2009; 201: 139, e1–e8.
24. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009; 56: 141–8.
25. Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
26. Shah NR, Jones JB, Aperi J et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111: 1175–82.
27. Freeman EW, Sammel MD, Lin H et al. Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 2011; 118: 1293–300.
28. Länden M, Nissbrandt H, Allgulander C et al. Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153–61.
29. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76.
30. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: 407–29.
31. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009; 105: 158–61.
32. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011; 8: 2.
33. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32: 42–51.
34. Hara R, Kino K. Enhanced synthesis of 5-hydroxy-L-tryptophan through tetrahydropterin regeneration. AMB Express 2013; 3: 70.
35. Carnevale G, Di Viesti V, Zavatti M, Zanoli P. Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine 2011; 18 (10): 848–51.
36. Emanuele E, Bertona M, Minoretti P, Geroldi D. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuro Endocrinol Lett 2010; 31 (5): 663–6.
37. Rondanelli M, Opizzi A, Faliva M et al. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord 2012; 17 (1): e22–28.
38. Prilepskaya VN, Ledina AV, Tagieva AV, Revazova FS. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006; 55 (Suppl. 1): S55–S63 (Scopus).
2. Yonkers KA, O’Brien S, Eriksson E. Premenstrual syndrome. Lancet 2008; 371 (9619): 1200–10.
3. Gollenberg AL, Hediger ML, Mumford SL et al. Perceived Stress and Severity of Perimenstrual Symptoms: The BioCycle Study. J Womens Health (Larchmt) 2010; 19 (5): 959–67.
4. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
5. Reed SC, Levin FR, Evans SM. Changes in Mood, Cognitive Performance and Appetite in the Late Luteal and Follicular Phases of the Menstrual Cycle in Women With and Without PMDD (Premenstrual Dysphoric Disorder). Horm Behav 2008; 54 (1): 185–93.
6. Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol 2010; 202 (3): 221–31.
7. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harv Rev Psychiatry 2009; 17 (2): 120–37.
8. Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, Sattar K. Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis Study. J Clin Diagn Res 2014; 8 (2): 106–9.
9. Epperson CN, Steiner M, Hartlage SA et al. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. Am J Psychiatry 2012;
169 (5): 465–75.
10. Wichianpitaya J, Taneepanichskul S. A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms. Obstet Gynecol Int 2013; 2013: 487143.
11. Forrester-Knauss C, Stutz EZ, Weiss C, Tschudin S. The interrelation between premenstrual syndrome and major depression: Results from a population-based sample. BMC Public Health 2011; 11: 795.
12. Read JR, Perz J, Ussher JM. Ways of coping with premenstrual change: development and validation of a premenstrual coping measure. BMC Womens Health 2014; 14: 1.
13. Borenstein J, Chiou CF, Dean B et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47: 26–33.
14. Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual Syndrome Prevalence and Fluctuation over Time: Results from a French Population-Based Survey. J Womens Health (Larchmt) 2009; 18 (1): 31–9.
15. Delara M, Borzuei H, Montazeri A. Premenstrual Disorders: Prevalence and Associated Factors in a Sample of Iranian Adolescents. Iran Red Crescent Med J 2013; 15 (8): 695–700.
16. Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006; 27 (4): 201–10.
17. Hartlage SA, Freels A, Gotman N, Yonkers KA. Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69 (3): 300–5.
18. O’Brien PMS, Bäckström T, Brown C et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 2011; 14: 13–21.
19. Payne JL, Palmer JT, Joffe H. A Reproductive Subtype of Depression: Conceptualizing Models and Moving Toward Etiology. Harv Rev Psychiatry 2009; 17 (2): 72–86.
20. Nevatte T, O’Brien PMS, Bäckström T et al. Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16 (4): 279–91.
21. Bäckström T, Haage D, Löfgren M et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011; 191: 46–54.
22. Andréen L, Nyberg S, Turkmen S et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009; 34: 1121–32.
23. Segebladh B, Borgström A, Nyberg S et al. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 2009; 201: 139, e1–e8.
24. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009; 56: 141–8.
25. Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
26. Shah NR, Jones JB, Aperi J et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111: 1175–82.
27. Freeman EW, Sammel MD, Lin H et al. Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 2011; 118: 1293–300.
28. Länden M, Nissbrandt H, Allgulander C et al. Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153–61.
29. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76.
30. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: 407–29.
31. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009; 105: 158–61.
32. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011; 8: 2.
33. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32: 42–51.
34. Hara R, Kino K. Enhanced synthesis of 5-hydroxy-L-tryptophan through tetrahydropterin regeneration. AMB Express 2013; 3: 70.
35. Carnevale G, Di Viesti V, Zavatti M, Zanoli P. Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine 2011; 18 (10): 848–51.
36. Emanuele E, Bertona M, Minoretti P, Geroldi D. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuro Endocrinol Lett 2010; 31 (5): 663–6.
37. Rondanelli M, Opizzi A, Faliva M et al. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord 2012; 17 (1): e22–28.
38. Prilepskaya VN, Ledina AV, Tagieva AV, Revazova FS. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006; 55 (Suppl. 1): S55–S63 (Scopus).
________________________________________________
1. Ледина А.В., Прилепская В.Н., Акимкин В.Г. Предменструальный синдром: распространенность и основные проявления (результаты эпидемиологического исследования). Эпидемиология и вакцинопрофилактика. 2014; 75 (2): 66–71.
2. Yonkers KA, O’Brien S, Eriksson E. Premenstrual syndrome. Lancet 2008; 371 (9619): 1200–10.
3. Gollenberg AL, Hediger ML, Mumford SL et al. Perceived Stress and Severity of Perimenstrual Symptoms: The BioCycle Study. J Womens Health (Larchmt) 2010; 19 (5): 959–67.
4. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
5. Reed SC, Levin FR, Evans SM. Changes in Mood, Cognitive Performance and Appetite in the Late Luteal and Follicular Phases of the Menstrual Cycle in Women With and Without PMDD (Premenstrual Dysphoric Disorder). Horm Behav 2008; 54 (1): 185–93.
6. Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol 2010; 202 (3): 221–31.
7. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harv Rev Psychiatry 2009; 17 (2): 120–37.
8. Direkvand-Moghadam A, Sayehmiri K, Delpisheh A, Sattar K. Epidemiology of Premenstrual Syndrome (PMS)-A Systematic Review and Meta-Analysis Study. J Clin Diagn Res 2014; 8 (2): 106–9.
9. Epperson CN, Steiner M, Hartlage SA et al. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. Am J Psychiatry 2012;
169 (5): 465–75.
10. Wichianpitaya J, Taneepanichskul S. A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms. Obstet Gynecol Int 2013; 2013: 487143.
11. Forrester-Knauss C, Stutz EZ, Weiss C, Tschudin S. The interrelation between premenstrual syndrome and major depression: Results from a population-based sample. BMC Public Health 2011; 11: 795.
12. Read JR, Perz J, Ussher JM. Ways of coping with premenstrual change: development and validation of a premenstrual coping measure. BMC Womens Health 2014; 14: 1.
13. Borenstein J, Chiou CF, Dean B et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005; 47: 26–33.
14. Potter J, Bouyer J, Trussell J, Moreau C. Premenstrual Syndrome Prevalence and Fluctuation over Time: Results from a French Population-Based Survey. J Womens Health (Larchmt) 2009; 18 (1): 31–9.
15. Delara M, Borzuei H, Montazeri A. Premenstrual Disorders: Prevalence and Associated Factors in a Sample of Iranian Adolescents. Iran Red Crescent Med J 2013; 15 (8): 695–700.
16. Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006; 27 (4): 201–10.
17. Hartlage SA, Freels A, Gotman N, Yonkers KA. Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69 (3): 300–5.
18. O’Brien PMS, Bäckström T, Brown C et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 2011; 14: 13–21.
19. Payne JL, Palmer JT, Joffe H. A Reproductive Subtype of Depression: Conceptualizing Models and Moving Toward Etiology. Harv Rev Psychiatry 2009; 17 (2): 72–86.
20. Nevatte T, O’Brien PMS, Bäckström T et al. Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16 (4): 279–91.
21. Bäckström T, Haage D, Löfgren M et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 2011; 191: 46–54.
22. Andréen L, Nyberg S, Turkmen S et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009; 34: 1121–32.
23. Segebladh B, Borgström A, Nyberg S et al. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 2009; 201: 139, e1–e8.
24. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009; 56: 141–8.
25. Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
26. Shah NR, Jones JB, Aperi J et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111: 1175–82.
27. Freeman EW, Sammel MD, Lin H et al. Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 2011; 118: 1293–300.
28. Länden M, Nissbrandt H, Allgulander C et al. Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007; 32: 153–61.
29. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995; 12: 167–76.
30. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: 407–29.
31. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 2009; 105: 158–61.
32. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 2011; 8: 2.
33. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32: 42–51.
34. Hara R, Kino K. Enhanced synthesis of 5-hydroxy-L-tryptophan through tetrahydropterin regeneration. AMB Express 2013; 3: 70.
35. Carnevale G, Di Viesti V, Zavatti M, Zanoli P. Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats. Phytomedicine 2011; 18 (10): 848–51.
36. Emanuele E, Bertona M, Minoretti P, Geroldi D. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuro Endocrinol Lett 2010; 31 (5): 663–6.
37. Rondanelli M, Opizzi A, Faliva M et al. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord 2012; 17 (1): e22–28.
38. Prilepskaya VN, Ledina AV, Tagieva AV, Revazova FS. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006; 55 (Suppl. 1): S55–S63 (Scopus).
Авторы
И.В.Кузнецова, В.В.Диль
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
________________________________________________
I.V. Kuznetsova, V.V. Dil
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.